Catawba Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Catawba Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-10,027	Closed	-$333K	–	229
2017 Q2	$333K	Sell	10,027 -890	-8%	-$27.5K	0.08%	174
2017 Q1	$350K	Sell	10,917 -10,367	-49%	-$354K	0.08%	188
2016 Q4	$772K	Sell	21,284 -7,370	-26%	-$294K	0.18%	119
2016 Q3	$1.32M	Hold	28,654	–	–	0.31%	82
2016 Q2	$1.44M	Buy	28,654 +100	+0.4%	+$5.32K	0.35%	78
2016 Q1	$1.53M	Hold	28,554	–	–	0.39%	73
2015 Q4	$1.87M	Sell	28,554 -10	-0%	-$618	0.51%	62
2015 Q3	$1.61M	Sell	28,564 -1,000	-3%	-$64.8K	0.44%	69
2015 Q2	$1.75M	Hold	29,564	–	–	0.42%	73
2015 Q1	$1.84M	Hold	29,564	–	–	0.42%	71
2014 Q4	$1.7M	Hold	29,564	–	–	0.39%	76
2014 Q3	$1.59M	Hold	29,564	–	–	0.37%	78
2014 Q2	$1.55M	Sell	29,564 -175	-0.6%	-$8.95K	0.35%	79
2014 Q1	$1.57M	Sell	29,739 -3,355	-10%	-$155K	0.37%	76
2013 Q4	$1.33M	Sell	33,094 -17,909	-35%	-$705K	0.32%	82
2013 Q3	$1.93M	Sell	51,003 -675	-1%	-$26.3K	0.5%	70
2013 Q2	$2.03M	Buy	+51,678	New	+$2.01M	0.56%	64

Other funds holding TEVA

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Catawba Capital Management's TEVA Position: Q3 2017 in Review

Catawba Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 10,027 shares — an estimated $333K sold.

Catawba Capital Management first reported a position in TEVA in Q2 2013 and held it in 17 quarters. The position peaked at $2.03M in Q2 2013. 537 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

Catawba Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Catawba Capital Management sold 10,027 Teva Pharmaceuticals shares in Q3 2017, an estimated $333K.
Catawba Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 17 quarters.
Catawba Capital Management's Teva Pharmaceuticals position peaked at $2.03M in Q2 2013.
537 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Catawba Capital Management's 13F filing for Q3 2017, filed 5 Oct 2017.